La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Laboratorios Farmaceuticos Rovi Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Juan Lopez-Belmonte Encina
Directeur général
€1.3m
Rémunération totale
Pourcentage du salaire du PDG | 55.2% |
Durée du mandat du directeur général | 17.6yrs |
Propriété du PDG | n/a |
Durée moyenne d'occupation des postes de direction | pas de données |
Durée moyenne du mandat des membres du conseil d'administration | 5.3yrs |
Mises à jour récentes de la gestion
Recent updates
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Jul 15We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Jun 17Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 06Analyse de la rémunération des PDG
Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
---|---|---|---|
Jun 30 2024 | n/a | n/a | €148m |
Mar 31 2024 | n/a | n/a | €138m |
Dec 31 2023 | €1m | €743k | €170m |
Sep 30 2023 | n/a | n/a | €197m |
Jun 30 2023 | n/a | n/a | €186m |
Mar 31 2023 | n/a | n/a | €194m |
Dec 31 2022 | €1m | €728k | €200m |
Sep 30 2022 | n/a | n/a | €176m |
Jun 30 2022 | n/a | n/a | €183m |
Mar 31 2022 | n/a | n/a | €182m |
Dec 31 2021 | €2m | €327k | €153m |
Sep 30 2021 | n/a | n/a | €113m |
Jun 30 2021 | n/a | n/a | €82m |
Mar 31 2021 | n/a | n/a | €71m |
Dec 31 2020 | €561k | €330k | €61m |
Sep 30 2020 | n/a | n/a | €55m |
Jun 30 2020 | n/a | n/a | €53m |
Mar 31 2020 | n/a | n/a | €46m |
Dec 31 2019 | €541k | €320k | €39m |
Sep 30 2019 | n/a | n/a | €33m |
Jun 30 2019 | n/a | n/a | €27m |
Mar 31 2019 | n/a | n/a | €18m |
Dec 31 2018 | €908k | €312k | €18m |
Sep 30 2018 | n/a | n/a | €16m |
Jun 30 2018 | n/a | n/a | €9m |
Mar 31 2018 | n/a | n/a | €18m |
Dec 31 2017 | €524k | €303k | €17m |
Rémunération vs marché: La rémunération totale de Juan ($USD 1.50M ) est dans la moyenne des entreprises de taille similaire sur le marché Spanish ($USD 1.50M ).
Rémunération et revenus: La rémunération de Juan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Juan Lopez-Belmonte Encina
17.6yrs
Titularisation
€1,346,000
Compensation
Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007 and served as its President from October 2020 to October 2022. He has been with L...
Membres du conseil d'administration
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Chairman & CEO | 17.1yrs | €1.35m | pas de données | |
Second Deputy Chairman & GM of Commercial and Development | 17.1yrs | €552.00k | pas de données | |
First Deputy Chairman | 17.1yrs | €554.00k | pas de données | |
Independent Director | 5.3yrs | €80.00k | pas de données | |
Independent Director | 4.7yrs | €80.00k | pas de données | |
Director | 2.3yrs | €80.00k | pas de données | |
Independent Director | 1.7yrs | €80.00k | pas de données |
5.3yrs
Durée moyenne de l'emploi
Conseil d'administration expérimenté: Les membres du conseil d'administration de ROVI sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).